Seasoned pharma executive Jonathan Symonds may chair GSK

By PharmaCompass

2019-07-18

Impressions: 112 Article

British drug major GlaxoSmithKline is all set to name Jonathan Symonds as its chairman. Symonds is a seasoned executive and has worked at both AstraZeneca and Novartis. GSK has been on the look out for a chairman for the last six months.

Currently, Symonds is the deputy chairman at HSBC Holdings Plc. His appointment is subject to approval from banking regulators, reports said. Symonds would replace Philip Hampton, who had said in January this year that he is stepping down.

The new chairman would oversee the consumer health joint venture GSK is setting up with Pfizer. The deal — announced in December 2018 — would spin out the unit formerly headed by GSK CEO Emma Walmsley and merge it with the equivalent division at Pfizer to create a new entity.

At GSK, Symonds would lead a team of seven non-executive directors alongside the three C-suite members sitting on the board. He would also oversee GSK’s shift in its R&D strategy, with a renewed attempt at developing some blockbuster cancer therapies. The drug behemoth is also focusing on growing its vaccines business.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass